Do Not Take Isosorbide Mononitrate CR at 8 PM to Replace a Missed Morning Dose
If you miss your morning dose of isosorbide mononitrate controlled-release, skip it entirely and take your next dose the following morning at the usual time. Do not attempt to make up for the missed dose by taking it later in the day.
Why Evening Dosing is Problematic
The controlled-release formulation is specifically designed to be taken in the morning upon arising 1. This timing is critical for several reasons:
Nitrate tolerance prevention: The medication provides therapeutic coverage for 12-24 hours after morning dosing, with plasma concentrations falling during the overnight period [@1,2,3,6@]. This creates a necessary "nitrate-free" or "nitrate-low" interval that prevents tolerance development [@15,17,19@].
Circadian rhythm alignment: Myocardial ischemia follows a marked circadian pattern, with the highest risk occurring in the hours immediately after waking 2. Morning dosing provides maximum protection during this critical period.
Rebound risk: Taking the medication at 8 PM would shift your therapeutic window to overnight and the following day, leaving you unprotected during the high-risk morning hours and potentially causing rebound ischemia when the drug wears off [@16,17@].
What to Do After a Missed Dose
Resume your normal schedule the next morning. The FDA-approved dosing is once daily in the morning 1. Studies demonstrate that this eccentric dosing pattern (with the overnight low-concentration period) maintains efficacy without tolerance development [@16,17,18@].
Important Caveats
Do not double dose: Never take two doses to compensate for a missed one, as this increases the risk of severe hypotension and headache 1.
Monitor for symptoms: If you experience angina after missing a dose, use sublingual nitroglycerin as needed for acute symptom relief [@1,2,3@].
Avoid pattern changes: Altering your dosing schedule to avoid headaches or for convenience can lead to loss of antianginal efficacy 1.
The controlled-release formulation's pharmacokinetics show that 30% releases immediately while 70% releases slowly over time [@14,15,23@]. This profile is optimized for morning administration and cannot be safely shifted to evening dosing without compromising both efficacy and safety.